- Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer ( Download)
- David Gandara, MD, current thinking regarding testing for PD-L1 biomarker in NSCLC patients ( Download)
- Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer ( Download)
- David Gandara, MD,, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients ( Download)
- PD-L1 agents in the treatment of NSCLC ( Download)
- PD-L1 as a Biomarker in Squamous Non-Small Cell Lung Cancer ( Download)
- Dr. Gandara on the MYSTIC Trial for Lung Cancer ( Download)
- Dr. Gandara Discusses the OAK Trial for Lung Cancer ( Download)
- Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC ( Download)
- Dr. Gandara on Practice-Changing Studies in Lung Cancer ( Download)
- Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care ( Download)
- David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC ( Download)
- Dr. Gandara on Online Treatment Decision Tool for Lung Cancer ( Download)
- David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results ( Download)
- Increasing treatment options for NSCLC ( Download)
